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Abstract: Methotrexate (MTX) is still
considered the drug of choice in rheumatoid
arthritis (RA) management. Comparing
subcutaneous (MTX SC) and oral (MTX OR)
routes of administration is important to
optimize the everyday therapeutic strategy in
the real-life setting. This review summarizes
scientific evidence currently available on this
topic. As shown by pharmacokinetic studies, at
the same dose level, bioavailability of MTX SC is
significantly higher and less variable than that
of MTX OR. This difference is even more
pronounced for medium-to-high dosages
(i.e.,[15 mg/week). With regard to clinical
response (Disease Activity Score-28, American
College of Rheumatology Criteria), randomized,
double-blind studies and retrospective or
longitudinal analyses in real-life settings
showed that MTX SC is more effective than
MTX OR. This is true both in MTX-naive
patients with early RA, and in patients who
switch from MTX OR to MTX SC due to
previous treatment failure, lack of efficacy
and/or adverse events. Finally, MTX SC has a
better tolerability profile than MTX OR, with
fewer gastroenterological side effects. Delaying
the use of more expensive biological therapies
by switching from MTX OR to MTX SC in
non-responders might provide cost savings,
with relevant implications in the management
of patients with RA.
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INTRODUCTION
Due to its relatively low cost and favorable
efficacy/safety profile, methotrexate (MTX) is
currently considered the drug of choice for
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treating rheumatoid arthritis (RA), both as
first-line monotherapy in treatment-naive
patients [1–4], and as an anchor drug, in
MTX-insufficient responders, in combination
with other conventional (csDMARDs) or
biological disease-modifying antirheumatic
drugs (bDMARDs) [3–5].
MTX optimization is therefore fundamental
in the effectivemanagement of patients with RA.
In this respect there are several aspects of utmost
importance, such as the starting and target doses
of MTX, the best treatment strategy [6–8], and
the optimal route of administration [9, 10]. In
fact, the choice of MTX route of administration
might significantly affect drug bioavailability,
thus influencing both its efficacy and
tolerability. The aim of this article is to review
the available evidence on differences in the
pharmacological characteristics and
corresponding clinical effects of oral (MTX OR)
and subcutaneous MTX (MTX SC) in patients
with RA. This review is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
SEARCH METHODS
The PubMed and Medline databases were
searched up to November 1, 2015 to identify
publications on the use of oral and subcutaneous
MTX usage in RA. A combination of relevant
keywords including methotrexate, subcutaneous
route, oral route, rheumatoid arthritis,
treatment, pharmacokinetic, efficacy and
toxicity were used (Table 1). Publications were
hand searched and selected for inclusion in the
review based on the authors experience in the
field (Table 2).
In particular, the references were first
selected from title and abstract, then included
or discarded after reading the full text. The
main inclusion criteria were studies comparing
MTX SC versus MTX OR in patients with RA.
BIOAVAILABILITY
The existence of different routes of MTX
administration (oral and parenteral) has led to
the conduction of pharmacokinetic studies
designed to compare and highlight any
significant differences in the drug’s therapeutic
impact. Several studies have demonstrated
higher bioavailability at various dosages with
MTX SC than with MTX OR (Table 3).
Differences appear to be especially marked at
MTX doses[15 mg/week.
In 1993, for the first time, Jundt et al. [11]
compared the pharmacokinetics of MTX at
various dosages in OR, intramuscular (IM) and
SC formulations in 12 patients with RA. The
authors showed that mean bioavailability was
significantly lower with MTX OR than with
MTX SC (0.85 vs. 0.97; P = 0.002; Table 3), and
that there was no significant difference between
the two parenteral routes of administration (IM
and SC). The authors attributed this difference
to intra- and inter-subject variability in the oral
absorption of the drug across the
gastrointestinal tract. These data were later
confirmed in a study comparing the
pharmacokinetics of MTX OR and MTX SC at
doses C25 mg/week (range 25–40 mg/week) in
15 patients with RA [12]. MTX OR
bioavailability was highly variable and
significantly lower (by about one-third;
P = 0.001) than that of MTX SC (Table 3).
A more recent randomized, open-label,
cross-over trial evaluated the pharmacokinetics
of MTX OR and MTX SC over a wide range of
doses, corresponding to those commonly used
in clinical practice (10, 15, 20, and 25 mg/
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week), in 47 patients with RA [13]. In
accordance with the study results, MTX SC
bioavailability was higher than that of MTX OR
across all tested doses with substantial
differences, from 20% to 40%, between the
two routes of administration (?21%, ?14%,
?31%, and ?41% for MTX 10, 15, 20, and
25 mg/week, respectively; Table 3). In
Table 1 Results of literature search
Modality of search No. references
resulting from
the search
No. references
included in
the study
References
PubMed and Medline query
Methotrexate and subcutaneous
(or parenteral) and oral and
rheumatoid arthritis
108 8 [11–17, 21, 23]
Methotrexate and subcutaneous
(or parenteral) and oral and
pharmacokinetic
19 2 [12, 13]
Methotrexate and subcutaneous
(or parenteral) and oral and
efﬁcacy
35 4 [12, 14, 17, 21]
Methotrexate and subcutaneous
(or parenteral) and oral and
toxicity
55 1 [21]
Other
Studies already known by authors
and/or cited in other articles
– 2 [18, 19]
Reviews, guidelines, other articles
already known by authors and/
or cited in other articles
– 12 [1–10, 20, 22]
Table 2 Characteristics of the literature included in the review
Kind of study No. References
Systematic review/guideline 5 [3, 4, 7, 20, 22]
Systematic review 5 [2, 5, 6, 9, 10]
Randomized, controlled, double blind 1 [14]
Randomized, controlled, open label 5 [8, 11–13, 15]
Prospective cohort study 1 [21]
Retrospective 4 [16–19]
Cost-minimization analysis 1 [23]
Expert opinion/editorial 1 [1]
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particular, a plateau effect was demonstrated for
MTX OR at doses above 15 mg/week, whilst
MTX SC showed a linear, dose-proportional
increase, with no ceiling effect up to the highest
dose of 25 mg/week.
EFFICACY AND TOLERABILITY
Growing evidence supports greater efficacy
(Tables 4, 5) and improved tolerability with
MTX SC compared with MTX OR in RA
management.
Clinical Trial Data
A multicenter, randomized, double-blind trial
assessed MTX efficacy and tolerability in
381 patients with active early RA (Disease
Activity Score-28 [DAS28] of[4), who were
MTX-naive [14]. At baseline, patients were
randomized to receive MTX OR or MTX SC at
15 mg/week, then if clinical response [defined
as a 20% improvement in American College of
Rheumatology Criteria (ACR20)] was not
achieved at week 16, patients originally
Table 3 Pharmacokinetic differences between MTX SC and MTX OR
MTX dose range tested Mean bioavailability References
7.5–17.5 mg/week MTX SC: 0.97 (95% CI 0.83–1.12)a
MTX OR: 0.85 (95% CI 0.77–0.93)
Jundt et al. [11]
25–40 mg/week MTX SC: 1.0
MTX OR: 0.64 (range 0.21–0.96)b
Hoekstra et al. [12]
10–25 mg/week Between group differences (MTX SC vs. MTX OR)
MTX 10 mg: ?21%
MTX 15 mg: ?14%
MTX 20 mg: ?31%
MTX 25 mg: ?41%
Schiff et al. [13]
CI conﬁdence intervals, MTX methotrexate, OR oral, SC subcutaneous
a P = 0.002 vs. MTX OR
b P = 0.001 vs. MTX SC
Table 4 Differences in clinical response between MTX SC and MTX OR
Outcome Duration of therapy,
monthsa
MTX SC MTX OR P value References
ACR20, % 6 78% 70% \0.05 Braun et al. [14]
ACR70, % 6 41% 33% \0.05
DAS28, mean (SD) 3 3.49 (1.50) 3.92 (1.48) 0.002 Hazlewood et al. [21]
DAS28, mean (SD) 6 3.12 (1.46) 3.50 (1.51) 0.011
DAS28, mean (SD) 9 2.79 (1.37) 3.23 (1.53) 0.005
Change of therapy, % 12 49% 77% \0.001 Hazlewood et al. [21]
ACR American College of Rheumatology, DAS Disease Activity Score, MTX methotrexate, OR oral, SC subcutaneous, SD
standard deviation
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assigned to MTX OR were switched to MTX SC
at the same dose (15 mg/week), while those
randomized to MTX SC ‘‘stepped-up’’ from 15 to
20 mg/week. After 6 months of treatment,
clinical response was significantly higher in
the MTX SC group than in the MTX OR group
(ACR20, 78% vs. 70%; ACR70, 41% vs. 33%;
Table 4). Inter-group differences were already
significant at 16 weeks of observation. After
16 weeks of treatment, overall 52 patients
(14%) were non-responders. ACR20 was
subsequently achieved in 23% MTX SC
recipients after a dose increase from 15 to
20 mg/week, and in 30% of MTX OR recipients
after switching to MTX SC (Table 5). There was
no significant difference in side effects between
the two treatment groups.
The CAMERA study (Computer Assisted
Management in Early RA) examined the efficacy
and tolerability of a conventional MTX
treatment approach compared with an
intensive treatment strategy, which involved
rapid stepwise increases in MTX OR dose by
5 mg/week every month up to a maximum dose
of 30 mg/week, with a switch to the same dose of
MTX SC in case of poor response or intolerable
adverse events, plus a further step of addition of
cyclosporine to MTX SC 15 mg/week [8]. A post
hoc analysis of this study, focused on the switch
from MTX OR to MTX SC, specifically in the
subset of patients originally assigned to the
intensive strategy, has been published [15].
Data from 57 of the 151 patients originally
randomized to the intensive therapy arm were
analyzed: 21 patients switched from MTX OR to
MTX SC due to adverse events and 36 patients
switched due to inadequate clinical efficacy.
Regardless of the reason for switching, a
statistically significant reduction in the mean
value of DAS28 was seen 1 month after the
switch, and for up to 4 months of evaluation
(P\0.05; Table 5).
The benefits of switching MTX route of
administration, from oral to parenteral, have
Table 5 Clinical response in patients switched from MTX OR to MTX SC because of treatment failure (inefﬁcacy or
toxicity)
Outcome Duration of
therapy, months
MTX SC References
ACR20, % 2 30 Braun et al. [14]
Mean reduction in DAS28 score 1 0.3 Bakker et al. [15]
4 0.5
DAS28 reduction of C1.2 points, % 6 74 Mainmann et al. [16]
DAS28 score\3.2, % 6 29
Improvement of DAS28, % 4 63 Bakker et al. [15]
Continuation rate, % 12 83 Scott et al. [17]
24 75
60 47
Additional biologic therapy, % 12 5.2 Scott et al. [17]
24 8.5
ACR American College of Rheumatology, DAS Disease Activity Score, MTX methotrexate; OR oral, SC subcutaneous
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also been confirmed in patients with
long-standing disease. In a retrospective
analysis, 78 patients receiving MTX SC
treatment, all of whom had previously failed
MTX OR therapy because of lack of efficacy or
side effects, were compared with 78 control
patients, responders to MTX OR monotherapy,
matched for disease duration (mean 5 years)
and baseline DAS scores [16]. Six months after
the switch, patients receiving MTX SC
experienced a significant improvement from
baseline in DAS28 scores, and showed final
levels of disease activity comparable with
responders to MTX OR (Table 5).
More recently, the MENTOR study
(Methotrexate Evaluation of Norwich
Treatment Outcomes in RA) evaluated the
short-, medium- and long-term effects (up to
5 years of follow-up) of a therapeutic switch
from MTX OR to MTX SC, due to intolerance
(43.9% of patients) or inefficacy (50.5% of
patients), in a cohort of 196 patients with
long-standing RA [17]. The switch to MTX SC
provided either a good long-term survival on
therapy (retention rates of 83% at 1 year, 75% at
2 years, and 47% at 5 years), and a minimal
need for further treatment with bDMARDs
(\10%; Table 5). Based on these results, the
authors suggested that the parenteral route of
administration should always be considered
before determining a patient’s overall failure
on or intolerance to MTX. In other words,
failure of MTX therapy should only be declared
in case of lack of efficacy of or intolerance to
MTX SC.
In addition, MTX SC seems to ensure better
tolerability and safety profiles, mainly with less
gastrointestinal discomfort for patients,
compared with MTX OR. Rutkowska-Sak et al.
[18] conducted an observational study based on
a patient-based questionnaire focusing on
gastrointestinal toxicity with MTX. A total of
70 patients with RA were initially treated with
MTX OR (7.5 or 15 mg/week), but switched to
MTX SC at the same dose because of side effects.
At both dosage levels, the switch from MTX OR
to MTX SC resulted in a marked improvement
in the subjective tolerability profile of the drug
with a significant reduction in the intensity of
nausea and abdominal pain and the
disappearance of vomiting and diarrhea.
Real-Life Data
Recently, the efficacy and safety data of MTX SC
have also been confirmed in several real-life
studies, far away from the controlled and
selected settings of clinical trials. A
retrospective analysis was conducted on a
cohort of 70 patients with RA in the St. Gallen
hospital in Switzerland who were MTX- and
csDMARD-naive, with the aim of evaluating the
efficacy, safety and tolerability of MTX SC in
real life [19]. Patients were initially treated with
MTX SC at various dosages ranging from 10 to
25 mg/week, according to treat-to-target and
tight control principles recommended in
current EULAR guidelines [20]. During the
mean observation period of 1.8 years,
37 patients (53%) continued MTX SC
monotherapy with clinical benefit, while
33 patients (47%) required addition of a
bDMARD due to incomplete disease control
[19]. On average, the use of the bDMARDs was
necessary in almost half of the patients after
approximately 1 year of treatment with MTX SC
(mean 387 days). Overall, most patients
achieved disease control [80% of patients had
low disease activity (LDA) and 73% achieved
clinical remission according to DAS28 score].
Furthermore, this result was achieved more
rapidly in the group treated with MTX SC
alone than in the group that required
combination therapy with bDMARDs: among
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patients treated with MTX SC monotherapy,
LDA was achieved within a mean of 111 days in
81.1% of patients, compared with a mean of
198 days in 78.8% of patients treated with
MTX ? bDMARDs. Similarly, DAS28 remission
was achieved by 75.7% of patients after a mean
of 145 days of MTX monotherapy, compared
with 69.7% of patients after a mean of 297 days
of MTX ? bDMARDs. During the study, the
discontinuation rate and the incidence of
adverse events were similar for both groups,
regardless of the addition of bDMARDs.
More recently, Hazlewood and co-authors
[21] compared the overall effectiveness of MTX
OR with MTX SC as initial therapy in
666 patients with early RA (symptoms for less
than 1 year). Patients were originally enrolled in
a multicenter, observational study in which the
choice of MTX route of administration was at
the discretion of the treating rheumatologist.
After 1 year of treatment a significantly higher
proportion of patients initially treated with
MTX OR (n = 417) had treatment failure
compared with those who received MTX SC
(n = 249; 77% vs. 49%, respectively; Table 4),
mostly due to lack of efficacy rather than
toxicity or intolerance to therapy. More
specifically, patients originally treated with
MTX OR had to increase the MTX dose, add or
switch to bDMARDs, and change the route of
administration much more frequently than
patients treated with MTX SC. After
adjustment for potential confounders related
to the non-randomized assignment of drug
formulation, MTX SC was closely linked to a
lower probability of global treatment failure
[hazard ratio 0.55; 95% confidence interval (CI)
0.39–0.79], justified primarily by a lower
probability of ineffectiveness of the drug.
Patients treated with MTX SC showed a more
significant reduction in mean DAS28 values at
3, 6, and 9 months after the beginning of
treatment compared with patients treated with
MTX OR (Table 4), with a significantly higher
probability of obtaining DAS28 clinical
remission (odds ratio 1.15; 95% CI 1.05–1.25;
P = 0.002).
DISCUSSION
Bioavailability data discussed herein are
reflected in the latest Italian recommendations
and guidelines on the management of RA [7,
22]. While guidelines permit a broad
therapeutic range (7.5–25.0 mg/week), the
optimal treatment strategy requires initial
doses higher than those recommended in the
past (12.5–15.0 mg/week). In addition, a specific
focus on MTX administered parenterally has
been added, with guidelines recommending
MTX SC both as first-line therapy and in
patients refractory to MTX OR, to ensure
higher bioavailability and thus achieve greater
clinical efficacy.
In support of this, clinical trial data
demonstrate that: (1) as initial therapy, MTX
SC is associated with greater clinical efficacy
than MTX OR at the same dosage level of
15 mg/week in MTX-naive patients with early
RA; (2) in cases of failure with MTX OR,
switching to MTX SC at the same dosage is
associated with attainment of a clinical
response in up to one-third more patients,
with no apparent increase in adverse
effects/toxicity; (3) in cases of no response to
MTX SC, dose step-up was efficacious and safe
[14]. The greater efficacy and flexibility of MTX
SC compared with MTX OR is mostly due to its
higher bioavailability at all possible dosages, but
especially at medium–high doses [11–13].
Real-life data also support the use of MTX SC
in routine care. MTX SC was shown to be an
effective and well-tolerated primary alternative
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to MTX OR in everyday clinical practice for
patients with early RA [19, 21].
Switching to MTX SC might also limit and
delay the eventualneed for further therapies,with
the possibility of an increased risk in terms of
adverse effects and costs. To this end, a recent
study examined the theoretical economic impact
ofMTX SC comparedwith biological drugs over a
12-month period in a hypothetical population of
RApatientswhohad failed to respond toMTXOR
[23]. The economic model was calculated using
published epidemiological and clinical data, and
referred to the National Institute for Health and
Clinical Excellence guidelines regarding the
labeled use of bDMARDs. On this hypothetical
background, in theUK, the routineuse ofMTXSC
after failure of MTX OR could potentially lead to
an estimated savings of £7197 per patient in the
first year of therapy and £9.3 million a year
nationally in new patients, due to the reduced
use of biological drugs [23].
CONCLUSIONS
In conclusion, in accordance with the latest
scientific evidence on the topic of MTX and RA,
we might consider the following observations:
1. From a pharmacokinetic standpoint, at the
same dosage, MTX SC has a significantly
higher bioavailabilitywith respect to the oral
route of administration. This difference is
even more pronounced for medium-to-high
dosages (i.e.,[15 mg/week).
2. MTX SC is a more flexible therapeutic
option than MTX OR, with a greater
potential in terms of dosage range. MTX
OR shows a plateau effect for dosages higher
than 15 mg/week, whilst MTX SC exhibits a
linear dose-dependent increase in
bioavailability up to high dosages (25 mg/
week).
3. From a therapeutic standpoint, both
clinical trials and real-life studies
demonstrate that MTX SC is superior to
MTX OR in terms of clinical efficacy (DAS28
and ACR response), either as first-line
therapy in MTX-naive patients, or in MTX
OR-experienced patients as switch therapy.
Clinical benefit has been demonstrated in
both early and long-standing disease.
4. MTX SC also shows a better tolerability
profile with respect to gastrointestinal
toxicity. Other side effects are similar
between parenteral and oral routes.
5. Overall, MTX SC is characterized by higher
bioavailability, greater clinical efficacy, and
a better tolerability profile than MTX OR.
Thus, current evidence suggests that the choice
ofMTX route of administration is a fundamental
parameter for optimizing RA treatment. The SC
route of administration seems to be the best
treatment option from the outset, in terms of
risk:benefit ratio compared with the oral route.
Finally, although to date there are no real
evidence of cost-effectiveness of MTX SC versus
MTC OR, it is possible to assume that delaying
the use of more aggressive and more expensive
therapies, such as bDMARDs, by switching from
MTX OR to MTX SC in non-responders might
provide cost savings while reducing risks, with
relevant implications in the everyday clinical
care of patients with RA. In this regard, a
specifically designed study to assess this
outcome would be desirable.
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